Cargando…
Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches
Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagn...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635713/ https://www.ncbi.nlm.nih.gov/pubmed/34868917 http://dx.doi.org/10.3389/fonc.2021.722507 |
_version_ | 1784608384304021504 |
---|---|
author | Diamantopoulos, Panagiotis T. Viniou, Nora-Athina |
author_facet | Diamantopoulos, Panagiotis T. Viniou, Nora-Athina |
author_sort | Diamantopoulos, Panagiotis T. |
collection | PubMed |
description | Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article. |
format | Online Article Text |
id | pubmed-8635713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86357132021-12-02 Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches Diamantopoulos, Panagiotis T. Viniou, Nora-Athina Front Oncol Oncology Atypical chronic myelogenous leukemia (aCML), BCR/ABL1 negative is a rare myelodysplastic/myeloproliferative neoplasm, usually manifested with hyperleukocytosis without monocytosis or basophilia, organomegaly, and marked dysgranulopoiesis. In this review, we will discuss the classification and diagnostic criteria of aCML, as these have been formulated during the past 30 years, with a focus on the recent advances in the molecular characterization of the disease. Although this entity does not have a definitive molecular profile, its molecular characterization has contributed to a better understanding and more accurate classification and diagnosis of aCML. At the same time, it has facilitated the identification of adverse prognostic factors and the stratification of patients according to their risk for leukemic transformation. What is more, the molecular characterization of the disease has expanded our therapeutic choices, thoroughly presented and analyzed in this review article. Frontiers Media S.A. 2021-11-17 /pmc/articles/PMC8635713/ /pubmed/34868917 http://dx.doi.org/10.3389/fonc.2021.722507 Text en Copyright © 2021 Diamantopoulos and Viniou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Diamantopoulos, Panagiotis T. Viniou, Nora-Athina Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title_full | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title_fullStr | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title_full_unstemmed | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title_short | Atypical Chronic Myelogenous Leukemia, BCR-ABL1 Negative: Diagnostic Criteria and Treatment Approaches |
title_sort | atypical chronic myelogenous leukemia, bcr-abl1 negative: diagnostic criteria and treatment approaches |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8635713/ https://www.ncbi.nlm.nih.gov/pubmed/34868917 http://dx.doi.org/10.3389/fonc.2021.722507 |
work_keys_str_mv | AT diamantopoulospanagiotist atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches AT viniounoraathina atypicalchronicmyelogenousleukemiabcrabl1negativediagnosticcriteriaandtreatmentapproaches |